Consequently, blockading HIF‐1α would appear to be a promising alternative therapy to alleviate advanced ARDS cases, including those resulting from combined acid plus small particles (CASP) aspiration lung injury. This evidence concerns the gene HIF1A and acute respiratory distress syndrome.